Evidence
Front Public Health. 2024 Apr 4;12:1322460. doi: 10.3389/fpubh.2024.1322460. eCollection 2024.
ABSTRACT
Chronic liver disease is a leading cause of death in the US and is often preventable. Rising burden, cost, and fatality due to liver disease are driven by intensified alcohol use in the US population and the contributions of comorbid conditions. This mini-review focuses on the topic of liver health in the context of chronic, behavioral cofactors of disease, using research-based examples from the Brown University Center for Addiction and Disease Risk Exacerbation (CADRE). Our aim is to illustrate the current challenges and opportunities in clinical research addressing liver health in the context of behavioral and medical comorbidity and to highlight next steps in this crucial area of public health research and clinical care.
PMID:38638470 | PMC:PMC11024463 | DOI:10.3389/fpubh.2024.1322460
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Alcohol-Related liver disease: A global perspective
- The gut-liver axis in fatty liver disease: role played by natural products
- New nomenclature for fatty liver disease
- COVID-19 in Individuals with Chronic Liver Diseases
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Role of lactate and lactate metabolism in liver diseases (Review)
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- Spatial genomics: mapping human steatotic liver disease
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
- FGL1 and FGL2: emerging regulators of liver health and disease
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Antidepressants in People With Chronic Liver Disease and Depression: When Are They Warranted and How to Choose the Suitable One?
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
- Liver cirrhosis in a patient with alcohol dependence and autoimmune hepatitis
- Alcohol, No Ordinary Commodity: policy implications for Canada
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- The epidemiological characteristics of liver disease in hospitalized children: a 10-year single-center retrospective study
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Interleukins in liver disease treatment
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Inflammatory liver diseases and susceptibility to sepsis
- The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Ocular manifestations of liver disease: an important diagnostic aid
- Ocular manifestations of liver disease: an important diagnostic aid
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry
- A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry
- Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Investigation of Markedly Elevated Liver Enzymes With Serendipitous Underlying Wilson's Disease With Chronic Alcohol Abuse
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
- Development of an alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell-derived liver organoids
- Development of an alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell-derived liver organoids
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- The LIVER CARE trial - screening for liver disease in individuals attending treatment for alcohol use disorder: a randomized controlled feasibility trial
- Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
- Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019
- Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- The role of sirtuin1 in liver injury: molecular mechanisms and novel therapeutic target
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
Evidence Blueprint
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Occult liver disease: a multinational perspective
- Alcohol-Related liver disease: A global perspective
- The gut-liver axis in fatty liver disease: role played by natural products
- New nomenclature for fatty liver disease
- Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study
- Fatty liver disease's renaming impacts on drug clinical trials
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease
- Omega-3 intake is associated with liver disease protection
- The effect of liver disease on hepatic microenvironment and implications for immune therapy
- Liver health and the interplay between obesity, alcohol and bariatric surgery
- COVID-19 in Individuals with Chronic Liver Diseases
- Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Role of lactate and lactate metabolism in liver diseases (Review)
- Health status of patients with liver transplantation by alcohol-related disease vs another etiology: a cohort study
- Therapeutic potential of oleanolic acid in liver diseases
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Hormone action and liver disease, a complex interplay
- Recent insight into the role of macrophage in alcohol-associated liver disease: a mini-review
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Integrated care models for co-occurring alcohol use disorders and alcohol-associated liver disease in rural communities: Telehealth considerations and opportunities
- Liver involvement in presence of heart disease and heart involvement in presence of liver disease: a conundrum
- The double roles of T cell-mediated immune response in the progression of MASLD
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- Alcohol, White Adipose Tissue, and Brown Adipose Tissue: Mechanistic Links to Lipogenesis and Lipolysis
- Spatial genomics: mapping human steatotic liver disease
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease
- Alcoholic liver disease - 2023
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology
- Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
- FGL1 and FGL2: emerging regulators of liver health and disease
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Impacts of gut microbiota alteration on age-related chronic liver diseases
- Corrected and republished from: Metabolic associated liver disease
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Antidepressants in People With Chronic Liver Disease and Depression: When Are They Warranted and How to Choose the Suitable One?
- Assessment and Evaluation of Alcohol Use Disorder in Liver Transplant
- Management of alcoholic hepatitis: A clinical perspective
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Interaction between Per- and Polyfluorinated Substances (PFAS) and Acetaminophen in Disease Exacerbation-Focusing on Autism and the Gut-Liver-Brain Axis
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
- Mitochondrial dysfunction: A promising therapeutic target for liver diseases
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Liver cirrhosis in a patient with alcohol dependence and autoimmune hepatitis
- Alcohol, No Ordinary Commodity: policy implications for Canada
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- The global burden of alcoholic liver disease: a systematic analysis of the global burden of disease study 2019
- The epidemiological characteristics of liver disease in hospitalized children: a 10-year single-center retrospective study
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Alcohol consumption and the risk of liver disease: a nationwide, population-based study